Tirzepatide Once Weekly for the Treatment of Obesity
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Obesity is a chronic disease that results in substantial global morbidity and mortality. The efficacy and safety of tirzepatide, a novel glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, in people with obesity are not known. METHODS: In this phase 3 double-blind, randomized, controlled trial, we assigned 2539 adults with a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of 30 or more, or 27 or more and at least one weight-related complication, excluding diabetes, in a 1:1:1:1 ratio to receive once-weekly, subcutaneous tirzepatide (5 mg, 10 mg, or 15 mg) or placebo for 72 weeks, including a 20-week dose-escalation period. Coprimary end points were the percentage change in weight from baseline and a weight reduction of 5% or more. The treatment-regimen estimand assessed effects regardless of treatment discontinuation in the intention-to-treat population. RESULTS: At baseline, the mean body weight was 104.8 kg, the mean BMI was 38.0, and 94.5% of participants had a BMI of 30 or higher. The mean percentage change in weight at week 72 was -15.0% (95% confidence interval [CI], -15.9 to -14.2) with 5-mg weekly doses of tirzepatide, -19.5% (95% CI, -20.4 to -18.5) with 10-mg doses, and -20.9% (95% CI, -21.8 to -19.9) with 15-mg doses and -3.1% (95% CI, -4.3 to -1.9) with placebo (P<0.001 for all comparisons with placebo). The percentage of participants who had weight reduction of 5% or more was 85% (95% CI, 82 to 89), 89% (95% CI, 86 to 92), and 91% (95% CI, 88 to 94) with 5 mg, 10 mg, and 15 mg of tirzepatide, respectively, and 35% (95% CI, 30 to 39) with placebo; 50% (95% CI, 46 to 54) and 57% (95% CI, 53 to 61) of participants in the 10-mg and 15-mg groups had a reduction in body weight of 20% or more, as compared with 3% (95% CI, 1 to 5) in the placebo group (P<0.001 for all comparisons with placebo). Improvements in all prespecified cardiometabolic measures were observed with tirzepatide. The most common adverse events with tirzepatide were gastrointestinal, and most were mild to moderate in severity, occurring primarily during dose escalation. Adverse events caused treatment discontinuation in 4.3%, 7.1%, 6.2%, and 2.6% of participants receiving 5-mg, 10-mg, and 15-mg tirzepatide doses and placebo, respectively. CONCLUSIONS: In this 72-week trial in participants with obesity, 5 mg, 10 mg, or 15 mg of tirzepatide once weekly provided substantial and sustained reductions in body weight. (Supported by Eli Lilly; SURMOUNT-1 ClinicalTrials.gov number, NCT04184622.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Many patients treated with GLP-1RAs achieve clinically meaningful weight loss while simultaneously demonstrating improvements in cardiometabolic health.45,46”
From Receipt of Glucagon-Like Peptide-1 Receptor Agonists Among Rural Patients with Obstructive Sleep Apnea and Excess Weight (2026) · cites this paper as [46]
In the citing paper
“with two articles presenting LM outcomes in only a subset of participants from the parent trial (6, 7).”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“Indeed, clinical trials demonstrate substantial weight loss achievable with GLP1Ra-based therapy, ranging from 12-15% over a one-year period for semaglutide (6), to weight losses rivaling what is seen with bariatric surgery for tirzepatide (7).”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“Across body weight and composition outcomes, the greatest magnitude of weight loss was observed in the SURMOUNT (7) and STEP (6) trials, respectively.”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“However, the magnitude of the treatment effect on total body mass was nearly two times greater in trials using GLP1Ra-based therapies at dosages indicated primarily for chronic weight management (6, 7, 18, 21, 24) as compared to trials using dosages indicated primarily for diabetes management (17, 19, 20, 22): −10.2 kg (−16.3, −3.9) versus −5.5 kg (−8.7, −2.1), respectively.”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
174 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Self-citationObesity and cardiovascular disease: a scientific statement from the American Heart Association
Powell-Wiley, T. M., Poirier, P., Burke, L. E., Després, J.-P., Gordon-Larsen, P., Lavie, C. J., Lear, S. A., Ndumele, C. E., Neeland, I. J., Sanders, P., et al. (2021) · Circulation · doi:10.1161/cir.0000000000000973 · Cited by 3,691
Di Angelantonio, E., Bhupathiraju, S. N., Wormser, D., Gao, P., Kaptoge, S., de Gonzalez, A. B., Cairns, B. J., Huxley, R., Jackson, C. L., Joshy, G., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30175-1 · Cited by 2,821
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
2. Classification and Diagnosis of Diabetes:Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s002 · Cited by 2,697
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096
Self-citationGarvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Self-citationObesity in adults: a clinical practice guideline
Wharton, S., Lau, D. C. W., Vallis, M., Sharma, A. M., Biertho, L., Campbell-Scherer, D., Adamo, K., Alberga, A., Bell, R., Boulé, N., et al. (2020) · Canadian Medical Association Journal · doi:10.1503/cmaj.191707 · Cited by 1,506
Self-citationRubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., et al. (2021) · JAMA · doi:10.1001/jama.2021.3224 · Cited by 1,444
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
Cited by
Items 3,301–3,400 of 3,704
Breakthrough drugs in the treatment of hypertension-related disease
Hoshide, S., Mogi, M., Shibata, S., Kishi, T., Usui, I., Ando, H., Nakagami, H., Nishiyama, A., Kario, K., & Japanese Society of Hypertension (JSH) Working Group on Emerging Pharmacological Therapies for Hypertension Management (2026) · Hypertension Research · doi:10.1038/s41440-026-02725-2
Demmel, J., Farrell, C., Timon, C., Cleary, O., Christie, H. L., O’Leary, N., George, C. V., Dunne, P., Mitchell, S., le Roux, C. W., et al. (2026) · International Journal of Pharmacy Practice · doi:10.1093/ijpp/riag090 · Cited by 2
Research Progress of Tirzepatide in Metabolic Diseases
孙, 豪. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.1672603
Demidova, T. Y., Izmaylova, M. Y., & Александровна, В. Н. (2026) · FOCUS Endocrinology · doi:10.62751/2713-0177-2026-7-2-08
Zhang, N., Long, Y., Xu, Z., Chen, G., Wang, A., Chen, W., Chen, Z., Liang, Z., Leung, K., & Chen, L. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.07.09.737400
Lipid sensing and brain hormone receptors in food intake and glucose regulation
Garrido, A. N., Lyons, S. A., MOSLEMIAN, D., Beaudry, J. L., & Lam, T. K. T. (2026) · Nature Reviews Endocrinology · doi:10.1038/s41574-026-01278-1
Kang, X., Liang, X., Cui, W., Song, Y., Wang, X., Hai, X., Wu, P., Hao, Y., Ma, X., & Yan, N. (2026) · Research Square · doi:10.21203/rs.3.rs-10330033/v1
Ritsinger, V., Lagerqvist, B., Ekström, M., Hagström, E., & Norhammar, A. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag367
Lari, S. A., Zumot, M. S., & Alrashid, M. A. (2026) · Cureus · doi:10.7759/cureus.112694
Demırcan, F., Özozan, Ö. V., & Gözel, N. (2026) · BMC Endocrine Disorders · doi:10.1186/s12902-026-02422-8
Off-Trial: Real-World Weight Loss on Tirzepatide and SemaglutidePreprint
Erly, B. K., & Raja, S. (2026) · medRxiv · doi:10.64898/2026.07.14.26357502
Examining Aging Related Female Adiposity Through the Endocrine Lens
Gülşen, M. R., Pal, L., & Lathief, S. (2026) · Healthy ageing and longevity · doi:10.1007/978-3-032-24097-2_6
Genomic Insights into Obesity in the Context of Aging and Longevity
Bhat, M. A., & Vanita, V. (2026) · Healthy ageing and longevity · doi:10.1007/978-3-032-24097-2_3
Clinical Application and Research Progress of Novel Anti-Obesity Medications
商, 博. (2026) · Pharmacy Information · doi:10.12677/pi.2026.154043
Du, J., Yang, Z., & Chen, Y. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1870484 · Cited by 1
Miličević, T., Cvitković, I., Volčanšek, Š., Katsiki, N., Mikhailidis, D. P., Patoulias, D., & Muzurović, E. M. (2026) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2026.2706660
Jonas, R., Planek, M. I. C., Hu, T., Evans, E., Brandon, M., Hankins, J., Patel, P., Arif, S., Thakker, J., Li, S., et al. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.125.043814
Peripheral artery disease: advances in medical therapy
Garagoli, F., Slipczuk, L. N., Shapiro, M. D., Bonaca, M. P., & Bhatt, D. L. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag516 · Cited by 3
Evolving utilization of bariatric surgery since the rise of semaglutide and tirzepatide
Kozato, A., Patel, S. S., Orandi, B. J., Massie, A. M., Mańkowski, M., Fielding, C. R., Segev, D. L., Parikh, M., & Chhabra, K. R. (2026) · Surgical Endoscopy · doi:10.1007/s00464-026-13147-z · Cited by 1
Maksimov, M. L., Sidorova, A. D., Kizlik, S. V., & Kizlik, V. A. (2026) · doi:10.33920/med-13-2603-01
Chan, T. C., Brennan, J. J., Killeen, J. P., & Castillo, E. M. (2026) · Emergency Care and Medicine · doi:10.3390/ecm3030022
CagriSema: a novel dual-pathway approach to target obesity and its complications
Calero, I. V., Rodríguez, A., & Frühbeck, G. (2026) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2026.101
EndoBridge 2025: pearls and highlights
Yıldız, B. O., Armenti, M., Brandi, M. L., Carey, J., Carling, T., Ciudin, A., Dhatariya, K., Fountas, A., Frühbeck, G., Goulis, D. G., et al. (2026) · HORMONES · doi:10.1007/s42000-026-00804-0 · Cited by 1
Pagel, P. S., Hang, D., Freed, J. K., & Crystal, G. J. (2026) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2026.07.032
Nakamura, A., Ichikawa, T., & Okuyama, K. (2026) · Hepatology Research · doi:10.1111/hepr.70249
Hellberg, A., Sundqvist, M. L., Hirschberg, A. L., Catrina, S., Eriksson, I., Ekberg, N. R., & Brismar, K. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27146460
Pedicino, D., & Liuzzo, G. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag550
Unconventional Applications of Semaglutide and Tirzepatide: From Oncology to Human Reproduction
Vignera, S. L., & Condorelli, R. A. (2026) · Biomedicines · doi:10.3390/biomedicines14071644 · Cited by 1
Li, J., Li, J., Xu, X., Wang, N., Lu, Y., & Wang, B. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03304-y
Xu, S. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71138 · Cited by 2
Ghusn, W., Matar, A., Annan, K. A., Sayegh, L., Gala, K. S., Ghanem, O. M., Maselli, D. B., Vargas, E. J., Dayyeh, B. K. A., & Storm, A. C. (2026) · Surgical Endoscopy · doi:10.1007/s00464-026-13151-3
Lipedema as a hormone-sensitive stromal disorder: a four-pathway translational framework
Viana, D. P. D. C., Invitti, A. L., & Schor, E. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1903835 · Cited by 1
Rashid, M., Lee, E. L., Veettil, S. K., Dhippayom, T., Cheng, A. Y. Y., SIMONETTI, J. S., & Chaiyakunapruk, N. (2026) · Obesity Reviews · doi:10.1111/obr.70198
LUBI, E. P., & Lubi, N. P. (2026) · RCMOS - Revista Científica Multidisciplinar O Saber · doi:10.51473/rcmos.v1i1.2026.2676
Palomo‐Piñón, S., Alcocer, L., Álvarez‐López, H., Enciso‐Muñoz, J. M., Galván‐Oseguera, H., Chávez‐Mendoza, A., Díaz‐Díaz, E., Muñoz, E. G. C., & Rosas-Peralta, M. (2026) · Annals of Clinical Hypertension · doi:10.29328/journal.ach.1001044
Kotlyarov, S. N., & Котлярова, А. А. (2026) · Pharmacoepidemiology · doi:10.3390/pharma5030025
Gao, S., & Borner, T. (2026) · Appetite · doi:10.1016/j.appet.2026.108723 · Cited by 2
Kamrul-Hasan, A. B. M., Khalil, I., Dutta, D., Mahajan, K., Nagendra, L., & Pappachan, J. M. (2026) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70291
Klassen, A. F., Rae, C. S., de Vries, C. E. E., Dalaei, F., Kaur, M. N., Gallo, L., Hoogbergen, M. M., Poulsen, L., Pusic, A. L., & Cano, S. (2026) · Obesity · doi:10.1002/oby.70254
Szentesi, A., Sipos, Z., Farkas, N., Dobszai, D., Cai, G., Vincze, Á., Sarlós, P., Gódi, S., Bajor, J., Hágendorn, R., et al. (2026) · Pancreatology · doi:10.1016/j.pan.2026.07.016
NEW ERA IN DIABETES AND OBESITY TREATMENT - THE EFFECTS OF GLP-1R, GIPR AND GCGR TRIAGONISTS
Duliński, M., Gofron, K. K., Kaźmierkiewicz, K., Spychalska, W., Piotrowicz, E., Witowicz, F., Glińska, J., Krawczyk, A., Waldon, W., & Sumlet, P. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(51).2026.6156
Barnett, A., Hosking, J., Tarrant, M., Creanor, S., Spencer, A. E., Ingram, W. M., Sanders, J., Swancutt, D. R., Lloyd, J., Sheaff, R., et al. (2026) · BMJ Open · doi:10.1136/bmjopen-2025-115791
Frank, A. L., Mohli, I., Kaur, N., & Arnold, W. (2026) · Cureus · doi:10.7759/cureus.113316
Schreurs, L., Baes, V., Kimpe, E., Marinus, H., der Schueren, B. V., & Cock, D. D. (2026) · Journal of Human Nutrition and Dietetics · doi:10.1111/jhn.70318
Vera-Ponce, V. J. (2026) · Obesity Pillars · doi:10.1016/j.obpill.2026.100308
Singla, A., Kaur, G., Singh, G., Luthra, S., Lodha, C., Alneser, O., Alo, M. S., Ali, S. K. S., & Zulqarnain, M. A. (2026) · Cureus · doi:10.7759/cureus.113371
Busetto, L., Contreras, C. O., Christensen, M. H., Garvey, T., Horn, D. B., McGowan, B. M., Miller, C. P., Schnecke, V., & le Roux, C. W. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71134
Eisa, N., Khoury, M., & Barood, O. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71161
Luthfiana, D., Dakiiwa, A., Shibata, T., & Kita, M. (2026) · Chemistry - An Asian Journal · doi:10.1002/asia.70906
Shegena, E. A., Kiflu, M., Ahmed, M. B., Bhagavathula, A. S., & Abegaz, T. M. (2026) · Obesity Reviews · doi:10.1111/obr.70200
Doğan, İ., Deniz, S. S., Bartın, M. K., Sönmez, E., Delice, M. C., Coban, S., & Çelik, S. (2026) · Medicina · doi:10.3390/medicina62081450
Varra, F., Theodosis‐Nobelos, P., Varra, V., & Varras, M. N. (2026) · Medicina · doi:10.3390/medicina62081445
Decoding Immunometabolic Dynamics of Adipose Tissue in Obesity: Evolving Evidence and Way Forward
Kumari, K., Verma, K., Yadav, R., Dwivedi, J., Paliwal, S., & Sharma, S. K. (2026) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.6c00071
Kalagi, F., Hamed, L., Alrubaian, S. S., Almuzain, F. A., Alturkestany, N., Bah, S., & AlGindan, Y. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1902763
Mapping Models of Tirzepatide Delivery for Obesity Management in Primary Care SettingsPreprint
Coulman, K. D., Rejon, C. S., Walter, S. R., Hollands, L., McHugh, C., Hollingworth, W., Lloyd, J., Tarrant, M., Redaniel, M. T., Judge, A., et al. (2026) · medRxiv · doi:10.64898/2026.07.24.26358784
Díaz, L. A. H., Alanis, B. A. L., Zorrilla-Núñez, L. F., & Muñoz-Maldonado, G. E. (2026) · Cureus · doi:10.7759/cureus.113460
Ahmed, M. M., Nazari, R., Othman, Z. K., Musa, S. S., Okesanya, O. J., Adebayo, U. O., Branda, F., Elmi, A. H., & Prisno, D. E. L. (2026) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188261472587 · Cited by 2
de Assis, D. C. M., Coelho, F. M. M., de Melo, P. M., & dos Santos, D. W. (2026) · Research Society and Development · doi:10.33448/rsd-v15i7.51433
Exploring on the Hyperinsulinism Management in Women with Polycystic Ovary Syndrome
de Medeiros, S. F., Yamamoto, M. M. W., Jacomeli, J., Soares, J. M., Maciel, G. A. R., & Baracat, E. C. (2026) · Journal of Gynecology and Obstetrics · doi:10.11648/j.jgo.20261403.12
Amioka, M., AMIOKA, H., Kinoshita, H., Sairaku, A., & Nakano, Y. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71162
Babazadeh, D., Zhong, H., & Steinberg, F. M. (2026) · Journal of Nutrition · doi:10.1016/j.tjnut.2026.101753 · Cited by 1
Bandaranaike, R., Rutland, T., & Rutland, B. (2026) · Euroasian Journal of Hepato-Gastroenterology · doi:10.5005/jp-journals-10018-1502
Castaneda, R., Sepulveda-Gonzalez, D., Andrade, M. D. H., SHUFELT, C. L., & Faubion, S. S. (2026) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000002854 · Cited by 3
Rivera‐Gonzalez, O., Liu, L., Gribble, F. M., Reimann, F., & Wess, J. (2026) · Science Advances · doi:10.1126/sciadv.aeb9805
Geraci, C., Rocca, F. L., Petrina, S. M., Buonauro, A., Morello, V., Paternò, V., Santoro, C., Geraci, G., & Esposito, R. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15155909
Wang, L., Jiang, F., Yuan, S., Sun, J., Zhao, J., Zhou, S., Liang, J., Li, H., Song, P., Wang, S., et al. (2026) · Metabolism · doi:10.1016/j.metabol.2026.156711
Shao, C., Lin, H., Yu, J., Chen, H., Ren, Y., Ren, J., Zeng, Y., Wu, Y., Zhang, Q., & Xiao, X. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71156 · Cited by 1
Ma, Y.-X., Lin, M., Nan, Y., Li, N.-N., Liu, B., Wang, H., Ning, S.-Y., & Zhang, Z. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1889437 · Cited by 3
Self-citationVenerito, V., Lopalco, G., Colaprico, C., et al. (2026) · RMD Open · doi:10.1136/rmdopen-2026-006830
Dass, A., Rohde, S. C., Wang, T. N., Chao, G. F., & Sweigert, P. J. (2026) · Surgery · doi:10.1016/j.surg.2026.110492
Garvey, W. T., Rosenstock, J., Bays, H. E., Denham, D. S., Kohli, A., Haines, M., Jones, C., Kwan, E., CASTELLOE, E. N., Marmon, T., et al. (2026) · Obesity · doi:10.1002/oby.70271
Burmeister, M. A., Brown, S. A., Greer, J. J., Hoggatt, T. J., & Zumwalt, W. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1925534
Mohamed, Z. I., Shidane, A. A., Abdiasis, A. M., Hussein, M. H., Ibrahim, A. O., Abdi, A. A., Hashi, K. I., Mohamud, M. A., & Mohamed, A. J. (2026) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70298
Dong, Z., Cheng, L., Shi, Q., Luo, Y., Ning, K., Ye, L., Tu, Y., & Shi, Z. (2026) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2026.153824
Changement dans la prise en charge de l’obésité : vision du clinicien
Montastier, É. (2026) · Biologie Aujourd hui · doi:10.1051/jbio/2026002
Tirzepatide for Severe Obesity in Adolescents Without Diabetes
Yehia, R., Patel, P., Sousa, E., & Vidmar, A. P. (2026) · AACE Endocrinology and Diabetes · doi:10.1016/j.aed.2026.07.013
Acute pancreatitis and its impact on mental health
Hoard, M., & Smith, Z. L. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-30263-3.00004-x
Review of the Relationship Between Obstructive Sleep Apnea and Atrial Fibrillation
Blacker, M. J., Rodriguez, L. D. R., Shah, C. D., Frishman, W. H., Aronow, W. S., & Rojas, R. (2026) · Cardiology in Review · doi:10.1097/crd.0000000000001408
MASLD and Cardiovascular Risk: Mechanisms and Implications for Clinical Practice
Li, S., Toutoungy, M., Patel, J., Bhavsar‐Burke, I., & VanWagner, L. B. (2026) · Current Hypertension Reports · doi:10.1007/s11906-026-01380-9 · Cited by 2
Pérez‐Pevida, B., Santana, M. S., Arriola, C. L., Maldonado, A., Clérigo, B., Ruiz, C., Higueruela, C., Ballesteros-Pomar, M. D., Lesmes, I. B., & Rodríguez, M. M. (2026) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2026.105005 · Cited by 1
Alsayed, O., Jarai, M. Z., Khan, S., & Sandal, M. (2026) · Cureus · doi:10.7759/cureus.113777 · Cited by 1
Tejera-Perez, C., Torrente, L., Porca, C., Bellido, D., & Crujeiras, A. B. (2026) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-026-10070-5 · Cited by 1
Anti-Obesity Medications in Longevity and Aesthetic Medicine
Bijoch, J. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15156026
Trends in GLP ‐1 Receptor Agonist Prescribing Without Documented Indications
Kim, C., Choi, K., Krumholz, H. M., & Lu, Y. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71153
Celebi, O., Gümüş, D., & Gümüş, Ö. (2026) · Healthcare · doi:10.3390/healthcare14152362
RNA-based approaches in the diagnosis and treatment of obesity
Parekh, K., & Sarker, G. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1882300 · Cited by 1
Agonists and Antagonists of the Human GIP Receptor
Kizilkaya, H. S., Gasbjerg, L. S., Holst, J. J., & Rosenkilde, M. M. (2026) · Wiley eBooks · doi:10.1002/9783527845408.ch2
Murugadoss, K., Venkatakrishnan, A., & Soundararajan, V. (2026) · Biology Methods and Protocols · doi:10.1093/biomethods/bpag043
GLP-1 receptor agonists and bariatric surgery: complement, not competition
Chumakova-Orin, M., Juo, Y.-Y., Fanelli, R. D., Irish, W. D., Pories, W. J., & DeMaria, E. J. (2026) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2026.07.021
Inamine, S., & Uesato, Y. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71190 · Cited by 1
The assembly of synthetically difficult “drug-like” macrocyclic peptides
Zhang, X., Guo, Y., Liu, F., & Yao, Z. (2026) · Chemical Communications · doi:10.1039/d6cc03294j
Oral Agents Used to Treat Type 2 Diabetes and Obesity
Liddle, J., Ratkova, E. L., Bonito, C. A., Rhodes, C. J., & Will, S. (2026) · Wiley eBooks · doi:10.1002/9783527845408.ch5
Ferreira, M. H. L., Câmara, L. C., Mattoso, S. O., Pereira, S. I. D. S., de Aguiar, D. R., & Khan, Z. U. (2026) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-026-02580-9
Chae, K., Jones, M. R., Yang, A., Ghosh, J., Rajagopal, S., & Chao, A. M. (2026) · Diabetes Obesity and Cardiometabolic CARE · doi:10.2337/doc26-0062
Ibrahim, E., Alaasmi, A., Mbionwu, U., Lastra, G., & Manrique‐Acevedo, C. (2026) · Physiology in health and disease · doi:10.1007/978-3-032-26472-5_9
Cho, C.-H., Yanagawa, A., & Kim, B. (2026) · Journal of Cosmetic Dermatology · doi:10.1111/jocd.71105
Laffin, L. J., Schlaich, M. P., Hall, M. E., Xie, C. C., Rao, G. S., Rettiganti, M., Dennehy, E. B., & Linetzky, B. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101783
Narla, S., & Narla, R. R. (2026) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2026.07.030 · Cited by 1
Impact of Personal Health Record Use on HbA1c Improvement in People with Type 2 Diabetes
Hanamura, I., Abiru, N., Sakamoto, T., Moriuchi, A., & Sera, N. (2026) · Diabetology · doi:10.3390/diabetology7090173
Wiater, D., Szkodziński, K., Jakubczyk, I., Maternia, J., Los, A. P. M., Majowicz-Czaszyńska, K. B., Pempuś, W., Król, N., Tomaszek, B., Blok, A., et al. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(51).2026.5814
Metadata
- Authors
- Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A.
- Affiliations
- Eli Lilly (United States) (US)
- From the Section of Endocrinology and Metabolism, Department of Medicine, and the Section of Pediatric Endocrinology, Department of Pediatrics, Yale University School of Medicine, New Haven, CT (A.M.J.); the Comprehensive Weight Control Center, Division of Endocrinology, Diabetes, and Metabolism, Weill Cornell Medicine, New York (L.J.A.); Eli Lilly, Indianapolis (N.N.A., S.Z., B.L., M.C.B., A.S.); McMaster University, Hamilton, and York University and Wharton Weight Management Clinic, Toronto — all in Ontario, Canada (S.W.); Intend Research, Norman, OK (L.C.); Centro Paulista De Investigação Clínica (Cepic), Sao Paulo (B.A.); and Tokyo-Eki Center-Building Clinic, Tokyo (A.K.).
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2022-07-21
- Volume
- 387
- Issue
- 3
- Pages
- 205-216
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4281934192
- Semantic Scholar
- 3fb03384cc726ebd9d08c76482e6edf35502d0c7
- Cited by
- 3,838
- References
- 28
- Citations by year
- 2026: 1279 · 2025: 1067 · 2024: 776 · 2023: 562 · 2022: 149
- FWCI
- 382.29
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- tirzepatide, obesity, weight loss, GLP-1 receptor agonists, GIP receptor agonist, glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, dose escalation, body mass index, weight-related comorbidities, treatment discontinuation, treatment-emergent adverse events, drug safety, subcutaneous administration
- MeSH terms
- Tirzepatide, Adult, Dose-Response Relationship, Drug, Double-Blind Method, Glucagon-Like Peptides, Gastric Inhibitory Polypeptide, Humans, Injections, Subcutaneous, Obesity, Weight Loss, Treatment Outcome, Anti-Obesity Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.